ADELAIDE, Australia,
April 10, 2015 /PRNewswire/ --
Bionomics Limited (ASX: BNO, OTCQX: BNOEF) today
announced that it will present a poster with new data on the
DisrupTOR-1 trial of BNC105 in patients with metastatic renal
cancer at the 7th Asian Oncology Summit being held from
April 10-12, 2015 in
Shanghai, China.
The poster will be presented by Dr. Jeremy Simpson, Vice President, Clinical
Development at Bionomics, and is entitled, A phase I/II trial of
BNC105P with everolimus in metastatic renal cell carcinoma (mRCC):
Results of the randomized phase II DisrupTOR-1 trial. The
Poster Walk session is during the Welcome Reception on Friday, April 10th, 2015 at 5:45 p.m. CST in the Mandarin Hall of the
Oriental Riverside Hotel and Convention Centre .
The data identify ferritin and IL-8 as two baseline biomarkers
that correlate with an improved progression free survival (PFS) in
patients. Eighty nine percent of patients expressing higher plasma
levels of ferritin and lower plasma levels of IL-8 at baseline were
disease progression-free at six months. The data show that
biomarker-based patient selection has the potential to optimise
clinical outcomes in the treatment of renal cancer. There are 6.3
new cases of renal cancer and 1.7 deaths per 100,000 people in
Asia each year.
BNC105 is a novel compound being developed as a vascular
disrupting agent (VDA) for the treatment of cancer. VDAs are drugs
that disrupt the blood vessels that nourish tumours. This approach
has a number of advantages over classical chemotherapy, including
stronger impact on tumour cell death, applicability to a wider
variety of cancers, and lowered risk of the emergence of
therapy-resistant tumour cells.
FOR FURTHER INFORMATION PLEASE CONTACT:
Bionomics
Limited
|
Monsoon
Communications
|
Stern
IR
|
Dr Deborah
Rathjen
|
Rudi
Michelson
|
Beth
DelGiacco
|
CEO & Managing
Director
|
+61 (0)3 9620 3333
|
+1 (212) 362 1200
|
+61 (0)8 8354 6101
|
rudim@monsoon.com.au
|
beth@sternir.com
|
0418 160 425
|
|
|
drathjen@bionomics.com.au
|
|
|
About Bionomics Limited
Bionomics (ASX: BNO)
is a biopharmaceutical company that discovers and develops
innovative therapeutics for cancer and diseases of the central
nervous system. Bionomics has small molecule product development
programs in the areas of cancer, anxiety, memory loss and pain. Its
oncology approach includes cancer stem cell therapeutics as well as
vascular disruption in solid tumours.
Bionomics' discovery and development are driven by its four
proprietary technology platforms: MultiCore®, a diversity
orientated chemistry platform for the discovery of small molecule
drugs; ionX® , a set of novel technologies for the identification
of drugs targeting ion channels for diseases of the central nervous
system; Angene®, a drug discovery platform that incorporates a
variety of genomics tools to identify and validate novel
angiogenesis targets (involved in the formation of new blood
vessels); and CSC Rx Discovery™, which identifies antibody and
small molecule therapeutics that inhibit the growth of cancer stem
cells. These platforms drive Bionomics' pipeline and underpin its
established business strategy of securing partners for its key
compounds. Bionomics' partners include Merck & Co.
www.bionomics.com.au
Factors Affecting Future Performance
This
announcement contains "forward-looking" statements within the
meaning of the United States'
Private Securities Litigation Reform Act of 1995. Any statements
contained in this presentation that relate to prospective events or
developments, including, without limitation, statements made
regarding Bionomics' development candidates BNC105, BNC210, BNC101
and BNC375, our acquisition of Eclipse Therapeutics and ability to
develop products from their platform, its licensing deals with
Merck & Co, drug discovery programs and pending patent
applications are deemed to be forward-looking statements. Words
such as "believes," "anticipates," "plans," "expects," "projects,"
"forecasts," "will" and similar expressions are intended to
identify forward-looking statements.
There are a number of important factors that could cause actual
results or events to differ materially from those indicated by
these forward-looking statements, including risks related to our
available funds or existing funding arrangements, a downturn in our
customers' markets, our failure to introduce new products or
technologies in a timely manner, Merck's decisions to continue or
not to continue development of partnered compounds, regulatory
changes, risks related to our international operations, our
inability to integrate acquired businesses and technologies into
our existing business and to our competitive advantages, as well as
other factors. Results of studies performed on competitors'
products may vary from those reported when tested in different
settings.
Subject to the requirements of any applicable legislation or the
listing rules of any stock exchange on which our securities are
quoted, we disclaim any intention or obligation to update any
forward-looking statements as a result of developments occurring
after the date of this presentation.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bnc105-biomarker-data-to-be-presented-at-asian-oncology-conference-300063987.html
SOURCE Bionomics Limited